Carregant...

Genotyping of cutaneous melanoma

Until recently, treatment options for patients with metastatic melanoma were very limited. This landscape has evolved dramatically since the discovery of activating mutations in the BRAF gene in ~45% of cutaneous melanomas. Vemurafenib, dabrafenib, and trametinib have all received regulatory approva...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Chin Clin Oncol
Autors principals: Glitza, Isabella C., Davies, Michael A.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4306428/
https://ncbi.nlm.nih.gov/pubmed/25632386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2304-3865.2014.03.01
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!